France
GENFIT is a late-stage biopharmaceutical company with a focus on improving the lives of patients with rare and severe liver diseases characterized by high unmet medical needs. With a history spanning over two decades, the company has shown prowess in developing high-potential assets, exemplified by the successful 52-week readout of its Phase 3 trial (ELATIVE®) evaluating elafibranor in Primary Biliary Cholangitis (PBC).
GENFIT's diversified R&D pipeline encompasses several therapeutic areas, with programs in acute on chronic liver failure (ACLF) in clinical and pre-clinical stages, targeting complications such as hepatic encephalopathy (HE). Additionally, the company has a Phase 2 clinical program aimed at cholangiocarcinoma and a preclinical program focused on urea cycle disorders (UCD) and organic acidemias (OA). Their diagnostic franchise primarily targets Metabolic dysfunction-associated steatohepatitis (MASH) and ammonia.
Founded in 1999 and headquartered in France, GENFIT is publicly traded on the Nasdaq Global Select Market and Euronext's regulated market in Paris (Nasdaq and Euronext: GNFT). In 2021, IPSEN became one of GENFIT's largest shareholders, holding 8% of the company's share capital and investing €26.50M in a Post-IPO Equity investment at 20 May 2025.
